Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Andrographolide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 19, 2018
Lead Product(s) : Andrographolide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Andrographolide
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2014
Lead Product(s) : Andrographolide
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Andrographolide
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Nutrition Science Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2013
Lead Product(s) : Andrographolide
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Nutrition Science Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Andrographolide
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2013
Lead Product(s) : Andrographolide
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable